Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGL-TX-GFR
2024-518773-33-00Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Kidney allograft status (RTx) and chronic kidney disease (CKD) comparing Forxiga with Placebo (2 arms). Primary endpoint: Chronic eGFR slope. Planned start Jun 2025; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
Kidney allograft status (RTx)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-518773-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518773-33-00.